Share your Ideas here. Be as descriptive as possible. Ask for feedback. If you find any interesting Idea, you can comment and encourage the person in taking it forward.
Dysmeno - A safe and affordable period cramp relief tablet
“Where Science Meets Comfort.”
The Problem:
- Almost 80% of menstruating women experience cramps ranging from moderate to severe and the current solutions to alleviate this pain are mostly over-the-counter painkillers (NSAIDs, paracetamol) or hormonal interventions (birth control pills), which often have side effects like gastric irritation, liver stress, risk of carcinogenicity and hormonal imbalance.
- High doses of the existing tablets coupled with cumulative dosage and age can increase likelihood of severe and adverse effects to our health.
Gap in the Market:
- Safety: Painkillers that are currently being used by most women today pose multiple risks to their health.
- Accessibility: In many regions, safe and affordable options are inaccessible.
Dysmeno attempts to fill this gap in the following ways:
- Non-carcinogenic & safe: Scientifically formulated to avoid long-term risks.
- Little to no side effects: Gentle on the stomach, liver, and overall metabolism.
- Affordable: Priced to be accessible to women across income groups.
- Fast-acting & effective: Provides relief within a short period.
- Natural + science-backed: Blend of natural extracts and clinically validated compounds to maximize relief and safety.
The Solution? - Dysmeno
- It is a tablet that performs the same functions as that of the existing painkillers without the adverse side effects being subjected to our health.
- Its composition is as follows:
- Standardized Ginger extract (Zingiber officinale) — 250 mg
- Fennel (Foeniculum vulgare) extract — 30 mg
- Curcumin (as phytosome or curcuminoid + piperine complex) — 250–500 mg curcuminoids equiv. + 5 mg piperine
- Magnesium (elemental Mg as magnesium citrate/magnesium oxide) — 125–250 mg elemental magnesium
- Vitamin B1 (Thiamine) — 50–100 mg
- Binder: microcrystalline cellulose (MCC)
- Disintegrant: croscarmellose sodium (2–5%)
- Lubricant: magnesium stearate (≤1%)
- Glidant: colloidal silicon dioxide (≤1%)
- Enteric coating, since gastric tolerance is a concern
- Uses a fast-dissolving core (to achieve goal: relief within 30–60 minutes)
Geographical focus:
- Urban and semi-urban areas with high awareness and accessibility to pharmacies.
- Expansion to rural areas through NGO/health initiatives.
- Global opportunity: Menstruation is universal; hence, the product has cross-border scalability.
Development of product:
- Formulation: The above mentioned combination of natural anti-inflammatory and antispasmodic ingredients.
- Dosage form: Small, easy-to-swallow tablet with fast dissolution.
- R&D process: Partner with pharmacologists, gynecologists, and biochemists to ensure safety and efficacy.
- Clinical trials: Phase-wise testing to establish safety, absence of carcinogenic effects, and effectiveness compared to NSAIDs.
Who does this product serve?
- Women and menstruators of all ages, from teenagers to working professionals and mothers.
- It serves those seeking a safe, affordable, and effective alternative to conventional painkillers, especially for regular monthly use without harmful side effects.
Why does this matter to me?
- This product will be important to many as it tackles one of the most common yet overlooked health concerns.
- I want to provide accessible, safe and efficient period painkillers to ensure the health and the quality of life of all women.
Road Map to the Market:
- Preclinical (0–1 yr): Formulation is finalized by in vitro and animal safety/toxicity studies per ICMR/GLP guidelines.
- Clinical Trials (1–4 yrs):
- Phase I: Small group (20–80, healthy volunteers) under CDSCO approval.
- Phase II: 100–200 women with dysmenorrhea, multi-center hospitals.
- Phase III: 1,000+ women across India, proving safety/efficacy.
- Regulatory Approval (2–4 yrs): Submit New Drug Application (NDA) to CDSCO / DCGI with trial data, CMC, and stability results.
- Manufacturing (3–4 yrs): Set up GMP-certified facility or partner with Indian pharma manufacturer; raw materials sourced under AYUSH/Pharma standards.
- Market Launch (4–5 yrs): Distribution via Jan Aushadhi stores, local pharmacies, and hospitals and online sales through e-pharmacy platforms (Pharmeasy, Tata 1mg).
